Jack h botting (78 résultats)

Hardcover. Etat : As New. Etat de la jaquette : No Jacket as Issued. This volume is the proceedings of the William Harvey Research Conference held in Cannes, France, on the 20th and 21st March, 1997. It describes the present knowledge of the structures of the cyclooxygenase isoforms and the experimental and clinical effects of selective inhibitors of cyclooxygenase-2.…

Hardcover. Etat : Very Good. VG+ hardcover. 150 pp.

Hardcover. Etat : Très bon. Ancien livre de bibliothèque avec équipements. Edition 1996. Ammareal reverse jusqu'à 15% du prix net de cet article à des organisations caritatives. ENGLISH DESCRIPTION Book Condition: Used, Very good. Former library book. Edition 1996. Ammareal gives back up to 15% of this item's net price to charity organizations.…

Cloth/Laminated Boards. Etat : Very Good. Etat de la jaquette : No d/j as Published. First Edition. Type: Book This volume is the proceedings of the William Harvey Research Conference held in Cannes, France, on the 20th and 21st March, 1997. It describes the present knowledge of the structures of the cyclooxygenase isoforms and the experimental and clinical effects of selective inhibitors of cyclooxygenase-2. The pathophysiological significance of the cyclooxygenase enzymes in tumorigenesis, programmed cell death, vascular disease and asthma is also covered.150pp.…

Cloth/Laminated Boards. Etat : Very Good. Etat de la jaquette : No d/j as Published. Reprint. Type: Book This volume is the proceedings of the William Harvey Research Conference held in Cannes, France, on the 20th and 21st March, 1997. It describes the present knowledge of the structures of the cyclooxygenase isoforms and the experimental and clinical effects of selective inhibitors of cyclooxygenase-2. The pathophysiological significance of the cyclooxygenase enzymes in tumorigenesis, programmed cell death, vascular disease and asthma is also covered.150pp.…

Cloth/Laminated Boards. Etat : Very Good. Etat de la jaquette : No d/j as Published. Type: Book This volume of conference proceedings reviews the general pathophysiological significance of the isoforms of cyclooxygenase, and the likely value of selective COX-2 inhibitors in the treatment of rheumatoid conditions. Also covered is the possible use of antibodies against cytokines and cell adhesion receptors in the treatment of inflammatory conditions. N.B.Top edge front board slightly bumped.147pp.…

Cloth. Etat : Like New. Etat de la jaquette : No d/j as Published. Type: Book This volume contains the proceedings of the William Harvey Conference held in London, 10-11 October, 1995. It covers the molecular biology and physiological functions of the cyclo-oxygenase enzymes, as well as the experimental and clinical aspects of the recently discovered inhibitors of the inducible cyclooxygenase. Particular attention has been directed at the discussion of the selectivity of non-steroid anti-inflammatory drugs for cyclooxygenase-2 and their propensity to cause gastric and kidney damage. 248pp.…

Hardcover. Etat : Near Fine condition. Etat de la jaquette : No Dust Jacket, as issued. First Edition. Dordrecht, Boston, London:: Kluwer Academic Publishers / William Harvey Press , 1996. Heavy erasure on title page else a bright, clean, square, tight copy. No owner's name or bookplate. No remainder marks. Pages are fresh and crisp. No underlining. No highlighting. No margin notes. Bound in the original maroon, pictorial boards. Proceedings of a Conference Held on October 10-11, 1995, at Regent's College, London. Contains 13 papers: 1) Overview - mechanisms of action of anti-inflammatory drugs; 2) The three-dimensional structure of cyclooxygenases; 3) The dilemma of two-cyclooxygenases: identifying the role of COX-1 and COX-2 in inflammation and apoptosis; 4) Inducible enzymes with special reference to COX-2 in the inflammatory response; 5) NSAID mechanism of action: the role of intracellular pharmacokinetics; 6) Differential inhibition of COX-1 and COX-2 in vitro and pharmacological profile in vivo of NSAIDs; 7) COX-2 expression and inhibition in human monocytes; 8) Expression and regulation of COX-2 in synovial tissues of arthritic patients; 9) An inhibitor of injury-induced COX-2 transcriptional activation elicits neuroprotection in a brain damage model; 10) COX-2 expression in labour; 11) Re-evaluation of gut toxicity of NSAIDs; 12) NSAID: can renal side effects be avoided?; 13) Pharmacology, safety data and therapeutics of COX-2 inhibitors. Bibliographical references. Index. From the rear cover: "This volume is the proceedings of the William Harvey Conference held in London on the 10th and 11th October, 1995. It covers the molecular biology and physiological functions of the cyclooxygenase enzymes, as well as the experimental and clinical aspects of the recently discovered inhibitors of the inducible cyclooxygenase. Particular attention has been directed at the discussion of the selectivity of non-steroid anti-inflammatory drugs for cyclooxygenase-2 and their propensity to cause gastric and kidney damage. Sir John Vane is the Director General, Regina Botting the Information Scientist, and Jack Botting Consultant at the William Harvey Research Institute, an independent charitable foundation carrying out research into cardiovascular disease inflammation and metabolic disorders within Queen Mary and Westfield College of the University of London, UK. Sir John Vane was awarded the Nobel Prize in 1982 for his discoveries of the mechanism of action of aspirin and of the physiological role of prostacyclin and other prostanoids.". First Edition. Hard Cover. Near Fine condition./No Dust Jacket, as issued. 8vo. ix, 241pp.…

Etat : New.

Etat : As New. Unread book in perfect condition.

Paperback. Etat : New.

Etat : New.

Etat : New. In English.

Etat : New. In English.

Etat : New. In English.

Etat : New. In English.

Etat : New. In English.

Etat : New. pp. ix + 150.

Etat : New. pp. 200.

Taschenbuch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - The mainstay of therapy for rheumatoid disease is the non-steroid antiinflammatory drugs (NSAIDs), despite their inherent gastrointestinal toxicity and ability to cause renal damage in susceptible patients. The theory that the beneficial and toxic effects of NSAIDs stem from a reduction in prostanoid production through inhibition of cyclooxygenase implied that particular toxicities were inevitable with NSAIDs and would always be correlated with efficacy. However, over the years, it became apparent that at therapeutic doses, some NSAIDs had greater toxic side-effects than others, a fact not explained by the general theory. A significant clarification arose from the discovery that there are two distinct isoforms of COX, a constitutive enzyme (COX-I) responsible for the production of prostanoids necessary for platelet aggregation and protection of the gastric mucosa and kidney; and an inducible enzyme (COX-2) that is newly synthesized at sites of tissue damage and produces prostaglandins that manifest pathological effects. It became clear that different NSAIDs had greater or lesser effects on COX-I when used in therapeutic doses, explaining the variation in side-effects. ' The elucidation of the crystal structure of these different enzymes and the skills of medicinal chemists have led to the synthesis of new chemicals with a selectivity for the inducible enzyme, and thus with therapeutic efficacy without those toxic effects result ing from inhibition of the constitutive enzyme.…

Taschenbuch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - In 1971, Vane proposed that the mechanism of action of the aspirin-like drugs was through their inhibition of prostaglandin biosynthesis. Since then, there has been intense interest in the interaction between this diverse group of inhibitors and the enzyme known as cyclooxygenase (COX). It exists in two isoforms, COX-l and COX-2 (discovered some 5 years ago). Over the last two decades several new drugs have reached the market based on COX-l enzyme screens. Elucidation of the three-dimensional structure of COX-l has provided a new understanding for the actions of COX inhibitors. The constitutive isoform of COX, COX-l has clear physiological functions. Its activation leads, for instance, to the production of prostacyclin which when released by the endothelium is anti-thrombogenic and anti-atherosclerotic, and in the gastric mucosa is cyto protective. COX-l also generates prostaglandins in the kidney, where they help to maintain blood flow and promote natriuresis. The inducible isoform, COX-2, was discovered through its activity being increased in a number of cells by pro inflammatory stimuli. A year or so later, COX-2 was identified as a distinct isoform encoded by a different gene from COX-I. COX-2 is induced by inflammatory stimuli and by cytokines in migratory and other cells. Thus the anti-inflammatory actions of non-steroid anti-inflammatory drugs (NSAIDs) may be due to the inhibition of COX-2, whereas the unwanted side-effects such as irritation of the stomach lining and toxic effects on the kidney are due to inhibition of the constitutive enzyme, COX-I.…

Taschenbuch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - For the past 100 years the mainstay of therapy for rheumatoid arthritis (RA) has been aspirin or other drugs of the non-steroid anti-inflammatory group. In 1971 Vane pro posed that both the beneficial and toxic actions of these drugs was through inhibition of prostaglandin synthesis. The recent discovery that prostaglandins responsible for pain and other symptoms at inflammatory foci are synthesized by an inducible cyclooxygenase (COX-2) that is encoded by a gene distinct from that of the consti tutive enzyme (COX-I) provided a new target for therapy of RA. A drug that would selectively inhibit COX-2 would hopefully produce the symptomatic benefit provided by existing NSAIDs without the gastrointestinal and renal toxicity due to the inhibition of COX-I. Drugs selective for COX-2 are now available. Experimental studies have shown them to be effective with minimal toxicity, and in clinical trials gastric and renal toxicities are less. Highly selective COX-2 inhibitors, perhaps designed with knowledge of the crystal structures of COX-I and COX-2, are also available. Other experimental studies, including those in animals lacking effective genes for COX-lor COX-2 and in experimental carcinomas, suggest there is still much to be learned of the pathophysiological functions of these enzymes. The inflammatory response is a complex reaction involving many mediators that derive from white blood cells, endothelial cells and other tissues. Preliminary data have revealed that inhibitors of the cytokines and adhesion molecules that play a crucial role in the migration of white cells to inflammatory sites may be useful in RA.…

Paperback. Etat : Brand New. 150 pages. 9.45x6.30x0.37 inches. In Stock.

Paperback. Etat : Brand New. 1996 edition. 160 pages. 9.25x6.10x0.47 inches. In Stock.

Paperback. Etat : Brand New. reprint edition. 248 pages. 8.75x6.00x0.75 inches. In Stock.

Taschenbuch. Etat : Neu. Selective COX-2 Inhibitors | Pharmacology, Clinical Effects and Therapeutic Potential | John R. Vane (u. a.) | Taschenbuch | ix | Englisch | 2012 | Springer | EAN 9789401060417 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu. …

Etat : New.

Etat : New.

Etat : New.

Etat : New.